| Comparison 5. Two IV antibiotics + inhaled antibiotic versus 2 IV without inhaled antibiotic for pulmonary exacerbations with P aeruginosa | ||||||
|---|---|---|---|---|---|---|
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| 2 IV without inhaled antibiotic | 2 IV antibiotic + inhaled antibiotic | |||||
| [IV ceftazidime + IV amikacin + inhaled amikacin versus IV ceftazidime + IV amikacin] Eradication of P aeruginosa Follow-up: 15 days | 409 per 1000 | 749 per 1000 (503 to 1000) | RR 1.83 (1.23 to 2.73) | 84 (Schaad 1987) | ⊕⊕⊕⊝ moderate1 | |
| [IV ceftazidime + IV amikacin + inhaled amikacin versus IV ceftazidime + IV amikacin] Adverse effects: raised liver transaminases Follow-up: 4 to 6 weeks | 250 per 1000 | 168 per 1000 (58 to 480) | RR 0.67 (0.23 to 1.92) | 54 (Schaad 1987) | ⊕⊝⊝⊝ very low1,2 | |
The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
The quality of the evidence was downgraded by 1 as 18 participants were recruited twice and 6 participants enrolled 3 times.
The quality of the evidence was downgraded by 2 due to serious imprecision as 95% CI crosses 2 default MIDs.
From: 9, Pulmonary monitoring, assessment and management
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.